Advanced Enzyme Q3 Results: Profit Bhaga **11%**, Par Revenue aur EBITDA Ka Kya Scene Hai?

CHEMICALS
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Advanced Enzyme Q3 Results: Profit Bhaga **11%**, Par Revenue aur EBITDA Ka Kya Scene Hai?
Overview

Advanced Enzyme ke investors ke liye mili-juli khabar hai. Company ne Q3 mein apna PAT **11%** tak badha liya hai, lekin revenue aur EBITDA mein thodi gadbad dikh rahi hai.

Okay, ab chalo thoda detail mein samjhte hain ki Advanced Enzyme Technologies ka kya haal raha Q3 FY26 mein.

Quarter Ki Performance (Q3 FY26 vs Q3 FY25)

Quarterly results dekhein toh revenue mein 2% ka halka sa jump tha, jo ₹1,719 million tak pahuncha. Par EBITDA 11% gir kar ₹494 million ho gaya. Achhi baat yeh hai ki PAT 11% badh kar ₹432 million raha. EBITDA margin 29% pe tha aur PAT margin 25%.

Sequentially Kya Hua? (Q3 FY26 vs Q2 FY26)

Agar pichhle quarter se compare karein, toh Q3 mein revenue 7% kam hua. EBITDA mein toh aur bhi badi giravat aayi, 18% neeche, aur PAT bhi 3% kam ho gaya. Matlab, sequentially performance thoda slow raha.

9 Mahine Ka Hisaab (9M FY26 vs 9M FY25)

Par 9 mahine ka hisaab dekhein toh picture kaafi achhi hai. Revenue 15% badha, EBITDA 11% upar gaya, aur PAT toh 20% ki zabardast growth dikha raha hai. EBITDA margin 31% pe hai aur PAT margin 24%.

Full Year FY25 Kaisa Raha?

Lekin full year FY25 ka report dekhne par thodi chinta hoti hai. Revenue sirf 2% badha, EBITDA 5% gir gaya, aur PAT bhi 2% kam ho gaya. Full year ke liye EBITDA margin bhi 33% se 31% ho gaya hai, matlab pressure hai. PAT margin bhi 22% se 21% ho gaya hai.

Aur Kya Hua?

Ek aur baat dhyan dene wali hai, Q3 aur 9 mahine mein ₹(112) million ka ek 'exceptional item' bhi dikha hai, jiska exact karan bataya nahi gaya.

Segments Aur Geography Ka Scene

Segments ki baat karein toh Animal Nutrition mein 22% (Q3) aur 26% (9M) ki growth dikhi, aur Industrial Bio-Processing mein bhi 13% (Q3) aur 15% (9M) ki badhotri hui. Human Nutrition mix raha. Geography mein India (+21% 9M) aur Asia ex-India (+60% 9M) ne accha kaam kiya, par Americas region mein Q3 mein 11% aur 9M mein 6% ki giravat aayi.

Financial Health Aur Aage Ka Plan

Company ka balance sheet toh strong hai, Net Worth ₹14,209 million hai aur debt bhi bahut kam hai. Lekin, ROE 9.76% aur ROCE 11.31% tak gir gaye hain FY25 mein. Management ka kehna hai ki woh R&D, expansion aur acquisitions par focus karenge, especially Animal Nutrition aur Bio-Catalysis jaise segments mein.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.